Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 75

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 75
---
Series E Alternate Optional Conversion Price” equal to the lesser of:

●The
applicable Series E Conversion Price, and

●the
greater of:

●the
floor price of $1.00; and

●95%
of the lowest volume weighted average price of the Common Stock during the five consecutive trading days immediately prior to such conversion.

31

Alternate Conversion
Upon a Triggering Event. Following the occurrence and during the continuance of a Triggering Event (as defined below), each holder
may alternatively elect to convert the Series E Preferred Stock at the “Series E Alternate Triggering Event Conversion Price”
(and together with the Series E Alternate Optional Conversion Price, each an “Series E Alternate Conversion Price”) equal
to the lesser of:

●The
applicable Series E Conversion Price, and

●the
greater of:

●the
floor price of $1.00; and

●90%
of the lowest volume weighted average price of the Common Stock during the five consecutive trading days immediately prior to such conversion.

The Series E Certificate
of Designations contains standard and customary triggering events (each, a “Series E Triggering Event”), including but not
limited to: (i) the suspension from trading or the failure to list the Common Stock within certain time periods; (ii) failure to declare
or pay any dividend when due; (iii) the failure to timely file or make effective a registration statement on Form S-1 or Form S-3 pursuant
to the Registration Rights Agreement (as defined below), (iv) the Company’s failure to cure a conversion failure or notice of the
Company’s intention not to comply with a request for conversion of any Series E Preferred Stock, and (iv) bankruptcy or insolvency
of the Company.

Other Adjustments.
In connection with the Private Placement, the Company has agreed to seek stockholder approval at a special meeting of stockholders, of
the issuance of Conversion Shares at a conversion price below the Series E Conversion Price (the date of such approval, the “Series
E Stockholder Approval Date”). If the Company has not otherwise obtained such stockholder approval prior to October 31, 2025, which
is not expected to occur, then the Company shall (i) file a preliminary Proxy Statement seeking such stockholder consent with the SEC
no later than October 31, 2025, (ii) use reasonable best efforts to file the definitive Proxy Statement no later than November 30, 2025
and (iii) use reasonable best